Methods for use in combination for the treatment and diagnosis of autoimmune diseases
This disclosure provides new genetic targets, diagnostic methods, and therapeutic treatment regimens for multiple autoimmune disorders, including pediatric autoimmune disorders that are co-inherited and genetically shared. The disclosure, for example, provides methods of diagnosing or determining a susceptibility for one or more autoimmune diseases and methods of determining treatment protocols for patients with one or more autoimmune diseases based on determining if the patients have genetic alterations in particular genes.
1. A method for detecting a single nucleotide variation (SNV) in rs2807264 on Xq26.3 in CD40LG in a celiac disease (CEL), ulcerative colitis (UC), or Crohn's disease (CD) human patient comprising:
a) obtaining a biological sample from the human patient; and
b) detecting a single nucleotide variation (SNV) in rs2807264 nucleic acid on Xq26.3 by contacting the sample with a probe specific for said SNV and detecting binding between said probe and said SNV nucleic acid.
2. The method of claim 1 , wherein the method further comprises detecting a single nucleotide variation (SNV) in at least one of IL23R, LPHN2, PTPN22, TNFSF18, CRB1, IL10, TSSC1, IL18R1, ATG16L1, GPR35, DAG1, CYTL1, IL21, TNM3, PTGER4, ANKRD55, ERAP2, IL5, IL12B, 8q24.23, JAK2, LURAP1L, TNFSF15, FNBP1, CARDS, IL2RA, ANKRD30A, ZNF365, ZMIZ1, NKX2-3, INS, LRRK2, SUOX, EFNB2, SMAD3, SBK1, ATXN2L, ADCY7, NOD2, IKZF3, TYK2, FUT2, TNFRSF6B, PSMG1, and RBMX.
3. The method of claim 1 , wherein the patient is a pediatric patient.
4. The method of claim 1 , wherein the method comprises treating UC, or CEL or CD by administering an anti-CD40LG antibody, CD40 antibody, or CD40LG inhibitor to the patient.
5. The method of claim 1 , wherein the method further comprises detecting a single nucleotide variation (SNV) in one or more of LPHN2, TNM3, and ADCY7.
6. The method claim 4 , wherein the method comprises treating ulcerative colitis (UC) and further comprises detecting a single nucleotide variation (SNV) in one or more of IL23R, LPHN2, DAG1, PTGER4, SBK1, TNFSF15, CD40LG, IL21, CARD9, and PSMG1.
7. The method of claim 6 , wherein the method further comprises detecting a single nucleotide variation (SNV) in one or more of IL10, TSSC1, IL18R1, GPR35, CYTL1, IL12B, JAK2, NKX2, SMAD3, ATXN2L, IKZF3, and TNFRSF6B.
8. The method of claim 4 , wherein the method comprises treating Crohn's Disease (CD) and further comprises detecting a single nucleotide variation (SNV) in one or more of IL23R, PTPN22, DAG1, ATG16L1, PTGER4, ANKRD55, LRRK2, SBK1, ADCY7, IL2RA, TNFSF15, ZMIZ1, IL21, CARD9, and PSMG1.
9. The method of claim 8 , wherein the method further comprises detecting a single nucleotide variation (SNV) in one or more of CRB1, IL10, TSSC1, IL18R1, CYTL1, ERAP2, IL5, IL12B, 8q24.23, JAK2, FNBP1, ZNF365, NKX2, SMAD3, ATXN2L, NOD2, IKZF3, TYK2, FUT2, TNFRSF6B, and RBMX.
10. The method of claim 1 , wherein the method comprises detecting a single nucleotide variation (SNV) in one or more of PTPN22, TNM3, SBK1, IL2RA, and IL21.
11. The method of claim 10 , wherein the method further comprises detecting a single nucleotide variation (SNV) in one or more of IL18R1, CYTL1, FNBP1, IKZF3, TYK2, and TNFRSF6B is present.
12. The method of claim 4 , wherein the method comprises treating Celiac Disease (CEL) and further comprises detecting a single nucleotide variation (SNV) in one or more of TNM3, DAG1, SBK1, IL2RA, ZMIZ1, or IL21.
13. The method of claim 12 , wherein the method further comprises detecting a single nucleotide variation (SNV) in one or more of IL18R1, CYTL1, ERAP2, IL5, IL12B, 8q24.23, IKZF3, or RBMX.